Impact of metabolic syndrome on clinicopathological characteristics and survival of patients with colorectal cancer / 中华全科医师杂志

ABSTRACT

Objective@#To examine the impact of metabolic syndrome (MS) on the clinicopathological characteristics and prognosis of patients with colorectal cancer (CRC).@*Methods@#The clinical data of 650 patients with CRC admitted in Shanxi Provincial Cancer Hospital between January 2010 and December 2011 were retrospectively analyzed. Among 650 patients there were 190 cases complicated with MS (MS group) and 460 cases without MS (non-MS group), the clinicopathological features and prognosis were compared between two groups.@*Results@#The serum insulin and insulin-like growth factor-1 (IGF-1) levels in MS group were significantly higher than those in non-MS group [(9.2±4.7) vs.(6.8±4.7)μIU/L, t=8.88, P<0.01 and (200.2±44.1) vs.(136.7±63.2)mg/L,t=12.63, P<0.01]. The proportions of stage T3 and T4 cancer, extra-regional lymph node metastasis (ELN), and TNM stage Ⅲ and Ⅳ patients in MS group were significantly higher than those in non-MS group [(83.2% (158/190) vs. 72.6% (334/460), χ2=8.19, P=0.04; 9.5% (18/190) vs. 4.8%(22/460),χ2=8.61, P=0.04; 56.3% (107/190) vs. 45.2%(208/460), χ2=8.22, P=0.04, respectively]. The 5-year disease-free survival (DFS) in MS group was significantly lower than that in non-MS group [57.9%(99/171)vs. 66.1%(279/422), P<0.01]. Multivariate analysis indicated that MS(HR=1.623, 95%CI1.511-1.963, P=0.03), IGF(HR=1.382, 95%CI1.031-1.765, P=0.02) and, ELN(HR=4.270, 95%CI2.177-7.463, P<0.01)were independent factors affecting the prognosis of CRC patients.@*Conclusion@#Metabolic syndrome is one of the risk factors affecting the prognosis of CRC patients.